BioSpace News Archive

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at the 2020 Solebury Trout Virtual Investor Conference on May 26, 2020 at 2:30 pm Eastern Time. Interested investors can access the live presentation as part of the Solebury Trout

Aegea Biotechnologies, Inc. ( “Aegea”) ( www.aegeabiotech.com), a biotechnology company focusing on the development and commercialization of next generation nucleic acid clinical diagnostic technologies, announces the issuance of 7 additional key US patents related to its core next generation nucleic acid clinical diagnostic technologies, including applications related to COVID-19 diagnostic testing under the c

JHL Biotech, Inc. today announced that the first group of subjects has been randomized and dosed last week in the company’s Australian Phase I Clinical Trial of JHL1266 in healthy subjects. The Three-A

Phase II clinical trial expected to be conducted at multiple centers in the United States, including three Mayo Clinic sites under the leadership of Andrew D. Badley, M.D., Enterprise Chair of COVID-19 Task Force Randomized, double blind, placebo-controlled clinical trial to be conducted in adults with COVID-19 who are hospitalized and either require supplemental oxygen or are on non-invasive ventilation or high flow oxygen devices BioS

- Met Primary Endpoint with a Correct Localization Rate of 84.8–87.0% - - 63.9% Change in Disease Management Plan Based on PyL Imaging Results - - Planned NDA Submission On Track for Early Third Quarter 2020 - NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that the results from the Phase 3 CONDOR trial evaluating the

The NCCN 2020 Annual Conference providing the latest updates on cancer treatment recommendations was initially postponed due to COVID-19.

The Prospective Clinico-Genomic Study aims to understand the cancer patient journey at scale by linking real-world clinical outcomes with genomic data, clinical images, and digital pathology data NEW YORK--( BUSINESS WIRE )-- Flatiron Health, Foundation Medicine, and Genentech, a member of the Roche Group, in partnership with community and academic oncology practices, have launched the Prospective Clinico-Genomic (PCG) Study, NCT04180176 . PCG is a n

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the resubmission of the Company’s New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for its ZIMHI ™ (naloxone HCI Injection, USP) 5mg/0.5mL product candidate for the treatment of opioid overdose. The resubmission follows the company’s meeting with the agency in February and is intended to address the issues raised by the FDA in the agency’s November 201

Lead asset Stendra® (avanafil) Looks to Build on $25 Million of 2019 Gross Sales Disruptive pipeline opportunity with topical treatment for Peyronie’s disease Neurotrope Bioscience, Inc. will continue as a separately traded entity with its lead Bryostatin program treating neurodegeneration Charles S. Ryan, J.D., Ph.D. named President and Chief Executive Officer of Petros

Castellum, Inc. (OTC: ONOV) announces General John F. Campbell has joined the Company’s Advisory Board. Castellum’s Advisory Board seats individual entrepreneurs and senior cyber security / information technology (IT) executives with business, government and technical expertise useful for assisting in identifying, integrating and growing acquired companies. General John F. Campbell served our country in the US Army for 37 years on active dut